ClinicalTrials.gg
Active, not recruitingNCT05425459Updated Mar 18, 2026

RESPONDER-HF Trial

An interventional study of Corvia Atrial Shunt System / IASD System II and Intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE) in Heart Failure and Heart Failure, Diastolic, sponsored by Corvia Medical. Active, not recruiting at 61 sites in 7 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-03-18.

Primary conditionHeart Failure, DiastolicRegistry: Heart FailureReclassifiedWhy we changed it
Registry
Heart Failure — the first condition term the registry derived for this study.
ClinicalTrials.gg
Heart Failure, Diastolic
Why
  1. The study's listed conditions name Heart Failure, Diastolic, a narrower term within Heart Failure.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Corvia Medical · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
750
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 95 studies in Heart Failure, Diastolic with a site in United States — 18 open to participants now, 20 under way, none of them phase 3. Heart Failure, Diastolic · United States.

Planned enrollment
6th of 81
750 · median 36
Started
2022
with 4 others
No phase
40 of 95
6 open now
Primary completion
2027-07
later than 9 of 19 live
Registered
75th of 95
by date

Among the 95 studies in Heart Failure, Diastolic with a site in United States, this one is the 6th largest by planned enrollment of the 81 interventional ones that give a count, is one of 5 that started in 2022, is one of 40 with no phase, reaches primary completion later than 9 of the 19 other live ones, and was the 75th registered.

Heart Failure, Diastolic

199 studies on the registry are indexed under Heart Failure, Diastolic; 44 are open to participants now.

Browse Heart Failure, Diastolic studies →

Open to participants now

18 of the 95 studies in Heart Failure, Diastolic with a site in United States are open now. Recruiting first, the newest first:

13 more — sign in →

All 18 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 29 Heart Failure, Diastolic studies recruiting now, 21 (72%) set no upper age limit and 4 (14%) stop at 75 or younger; 3 take children under 18; 6 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 95 studies in Heart Failure, Diastolic with a site in United States, or all of them as a file.
02

Study summary

Multicenter, Prospective, Randomized, Sham Controlled, Double Blinded Clinical Trial, with; 1:1 randomization

Read the detailed description

Following supine bicycle exercise hemodynamic assessment to verify eligibility, patients are sedated then randomized to the treatment or control group. Patients in both arms will undergo placement of femoral venous access sheath.

Patients randomized to the treatment arm will undergo a fluoroscopically and intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE) guided trans-septal puncture and Corvia Atrial Shunt implant procedure. Patients randomized to the control arm will undergo ICE from the femoral vein or TEE for examination of the atrial septum and left atrium.

Patients will be evaluated at pre-specified time intervals and followed for 5 years.

All patients will be unblinded after the 24 month follow up visit.

03

Conditions studied

  • Heart Failure
  • Heart Failure, Diastolic

Browse trials for

Keywords

  • Heart failure with preserved ejection fraction (HFpEF)
  • Heart failure with midrange ejection fraction (HFmrEF)
  • Interatrial Shunt
04

In context

Heart Failure, Diastolic Reclassified

199 studies on the registry are indexed under Heart Failure, Diastolic; 44 are open to participants now.

This study's planned enrollment of 750 is above the median of 48 across 139 interventional studies indexed under Heart Failure, Diastolic.

Browse Heart Failure, Diastolic studies →

Lead sponsor

Corvia Medical is the lead sponsor of 8 studies on the registry; none are open to participants now.

Compared within Heart Failure, Diastolic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Heart Failure. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Chronic symptomatic heart failure (HF) documented by the following:

    1. Symptoms of HF requiring current treatment with diuretics if tolerated for ≥ 30 days AND
    2. (NYHA) class II; OR NYHA class III, or ambulatory NYHA class IV symptoms; AND
    3. ≥ 1 HF hospital admission (with HF as the primary, or secondary diagnosis); or treatment with intravenous (IV) diuretics; or intensification of oral diuresis within the 12 months prior to study entry; OR an NT-proB-type Natriuretic Peptide (NT-pro BNP) value > 150 pg/ml in normal sinus rhythm, > 450 pg/ml in atrial fibrillation, or a brain natriuretic peptide (BNP) value > 50 pg/ml in normal sinus rhythm, > 150 pg/ml in atrial fibrillation within the past 6 months
  2. Ongoing stable guideline-directed medical therapy (GDMT) HF management and management of comorbidities according to the 2022 American College of Cardiology (ACC)/American Heart Association (AHA) Guidelines for the Management of Heart Failure. Stable management includes a minimum period of 4 weeks post-hospitalization for any cause, including treatment with IV diuretics
  3. Site determined echocardiographic LV ≥ 40% within the past 6 months, without documented ejection fraction \< 30% in the 5 years prior.
  4. Site determined echocardiographic evidence of diastolic dysfunction documented by one or more of the following:

    1. Left Atrial (LA) diameter > 4 cm; or
    2. Diastolic LA volume > 50 or LA volume index > 28 ml/m2 or
    3. Lateral e' \< 10 cm/s; or
    4. e' \< 8 cm/s; or
  5. Site determined elevated pulmonary capillary wedge pressure (PCWP) with a gradient compared to right atrial pressure (RAP) documented by end-expiratory PCWP during supine ergometer exercise ≥ 25 millimeters of mercury (mm Hg), and greater than RAP by ≥ 5 mm Hg.
  6. Resting RAP ≤ 14 mmHg
  7. Site determined hemodynamic evidence of peak exercise pulmonary vascular resistance (PVR) \< 1.75 Wood units
  8. Age ≥ 40 years old
  9. Participant has been informed of the nature of the study, agrees to its provisions and has provided written , approved by the Institutional Review Board (IRB) or Ethics Committee (EC)
  10. Participant is willing to comply with clinical investigation procedures and agrees to return for all required follow-up visits, tests, and exams
  11. Transseptal catheterization and femoral vein access to the right atrium is determined to be feasible by site interventional cardiology investigator.

Exclusion criteria

Exclusion Criteria:

  1. Advanced heart failure defined as one or more of the below:

    1. ACC/AHA/European Society of Cardiology (ESC) Stage D heart failure, non-ambulatory Class IV HF
    2. Cardiac index \< 2.0 L/min/m2
    3. Inotropic infusion (continuous or intermittent) for EF \< 40% within the past 6 months
    4. Patient is on the cardiac transplant waiting list.
  2. Inability to perform 6-minute walk test (distance \< 50 meters), OR 6-minute walk test > 600m
  3. The patient has verified that the ability to walk 6 minutes is limited primarily by joint, foot, leg, hip or back pain; unsteadiness or dizziness or lifestyle (and not by shortness of breath and/or fatigue and/or chest pain)
  4. Right ventricular dysfunction, assessed by the site cardiologist and defined as one or more of the following:

    1. More than mild right ventricular (RV) dysfunction as estimated by transthoracic echocardiogram (TTE); OR
    2. TAPSE \< 1.4 cm; OR
    3. Right ventricular (RV) size ≥ left ventricular (LV) size as estimated by TTE; OR
    4. Ultrasound or clinical evidence of congestive hepatopathy; OR
    5. Evidence of RV dysfunction defined by TTE as an RV fractional area change \< 35%.
  5. Any implanted cardiac rhythm device
  6. Structural heart repair aortic valve replacement (AVR) or mitral valve replacement (MVR) (surgical or percutaneous) within the past 12 months; planned valve intervention in the next 3 months, or presence of hemodynamically significant valve disease as assessed by the site cardiologist and defined as:

    1. Mitral valve disease grade ≥ 3+ mitral regurgitation (MR) or > mild Mitral Stenosis (MS); OR
    2. Tricuspid valve (TR) regurgitation grade ≥ 2+ TR; OR
    3. Aortic valve disease ≥ 2+ aortic regurgitation (AR) or > moderate aortic stenosis (AS)
  7. Echocardiographic evidence of intra-cardiac mass, thrombus or vegetation
  8. Participants with existing or surgically closed (with a patch) atrial septal defects. Participants with a patent foramen ovale (PFO), who meet PCWP criteria despite the PFO, are not excluded
  9. Myocardial Infarction (MI) and/or percutaneous cardiac intervention within past 3 months; Coronary Artery Bypass Graft (CABG) surgery in past 3 months or any planned cardiac interventions in the 3 months following enrollment.
  10. Known un-revascularized coronary artery disease, defined as: coronary artery stenosis with angina or other evidence of ongoing active coronary ischemia
  11. Known clinically significant untreated carotid artery stenosis likely to require intervention
  12. Atrial fibrillation with resting heart rate (HR) > 100 beats-per-minute (BPM)
  13. Hypertrophic obstructive cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, cardiac amyloidosis or infiltrative cardiomyopathy (e.g. hemochromatosis, sarcoidosis)
  14. History of stroke, (TIA), deep vein thrombosis (DVT), or pulmonary emboli within the past 6 months
  15. Participant is to receive either dual antiplatelet therapy, or an oral anticoagulant; or has a documented coagulopathy
  16. Anemia with \< 10 g/dl
  17. Chronic pulmonary disease requiring continuous home oxygen, OR significant chronic pulmonary disease defined as forced expiratory volume (FEV)1 \<1Liter
  18. Resting arterial oxygen saturation \< 95% on room air, \<93% when residing at high altitude
  19. Currently requiring dialysis; or estimated eGFR \< 25ml/min/1.73 m2 by chronic kidney disease (CKD) CKD-Epi equation
  20. Systolic blood pressure > 170 mm Hg at screening
  21. Significant hepatic impairment defined as 3 times of transaminases, total , or alkaline phosphatase
  22. Participants on significant treatment or on systemic treatment
  23. less than 12 months for known non-cardiovascular reasons
  24. Known to nickel or titanium
  25. Women of
  26. Severe obstructive sleep apnea not treated with continuous positive airway pressure (CPAP) or other measures
  27. (BMI) > 45; BMI 40 - 45 is also excluded unless in the opinion of the investigator, vascular access can be obtained safely
  28. Severe depression and/or anxiety
  29. Currently participating in an drug or device study that would interfere with the conduct or results of this study. Note: trials requiring extended follow-up for products that were investigational but have since become commercially available are not considered investigational
  30. In the opinion of the investigator, the Participant is not an appropriate candidate for the study.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
750 participants (estimated)

Study arms

  • Experimental
    Treatment

    Participants randomized to the treatment arm will undergo a fluoroscopic and intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE) guided trans-septal puncture and InterAtrial Shunt Device (IASD) System II implant procedure.

    Device: Corvia Atrial Shunt System / IASD System II

  • Sham comparator
    Control

    Participants randomized to the control arm will undergo fluoroscopy and intracardiac echocardiography from the femoral vein or transesophageal echocardiography, for examination of the atrial septum and left atrial appendage.

    Other: Intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE)

Interventions

  • DeviceCorvia Atrial Shunt System / IASD System II

    The primary component of the system is an implant placed in the atrial septum designed to allow left to right flow between the left atrium and right atrium to reduce the elevated left atrial pressure.

  • OtherIntra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE)

    Intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE) for examination of the atrial septum and left atrium.

07

What researchers measure

Primary outcomes

  1. Composite Primary Endpoint

    The primary endpoint is a composite of heart failure event rates and Kansas City Cardiomyopathy Questionnaire (KCCQ) at 12 months. Responses are given on a Likert scale that for each individual item is scored on a scale of 0-100 with higher scores indicating better health.

    Time frame: Up to 12 months

Secondary outcomes

  1. The incidence of cardiovascular mortality

    The incidence of cardiovascular mortality through 12 months.

    Time frame: Up to 12 months

  2. The rate of time-to-cardiovascular mortality

    Time-to-cardiovascular mortality through 12 months.

    Time frame: Up to 12 months

  3. The rate of major adverse cardiac periprocedural events

    Major adverse cardiac periprocedural events through 30 days defined as: 1. Cardiac death 2. Myocardial infarction 3. Cardiac tamponade 4. Emergency cardiac surgery.

    Time frame: Through 30 days

  4. The incidence of non-fatal, ischemic stroke

    Incidence of non-fatal, ischemic stroke

    Time frame: Through 12 months

  5. The rate of new onset or worsening of kidney dysfunction

    New onset or worsening of kidney dysfunction (defined as estimated glomerular filtration rate (eGFR) decrease of \> 20 ml/min/1.73 m2) through 12 months

    Time frame: Through 12 months

  6. The incidence of thrombo-embolic complications including transient ischaemic attack (TIA) and systemic embolization)

    The incidence of thrombo-embolic complications (TIA and systemic embolization) through 12 months

    Time frame: Through 12 months

  7. The incidence of newly acquired persistent or permanent atrial fibrillation (AF) or atrial flutter

    The incidence of newly acquired persistent or permanent AF or atrial flutter

    Time frame: Through 12 months

  8. The incidence of participants with a ≥30% decrease in Tricuspid Annular Plane Systolic Excursion (TAPSE)

    The incidence of participants with a ≥30% decrease Tricuspid Annular Plane Systolic Excursion (TAPSE)

    Time frame: Through 12 months

  9. The rate of heart failure (HF) admissions

    Total rate (first plus recurrent) per patient year of heart failure (HF) admissions or healthcare facility visits for intravenous diuresis or urgent visits with intensification of oral diuresis for HF through 24 months, analyzed when the last randomized participant completes 12 months follow-up.

    Time frame: Through 24 months

  10. The change in New York Heart Association (NYHA) Class

    Change in NYHA functional Class between baseline and 12 months

    Time frame: 12 months

  11. The change in Kansas City Cardiomyopathy Questionnaire (KCCQ) Score

    Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) Score between baseline and 12 months, categorized as proportion of patients with changes of ≤0, \>0 - 5, \>5 - 10, \>10 - 15, \>15 - 20, \>20 - 25, \>25 points. Responses are given on a Likert scale that for each individual item is scored on a scale of 0-100 with higher scores indicating better health

    Time frame: 12 months

08

Study locations

61 sites
09

References and documents

Publications

  • Borlaug BA, Blair J, Bergmann MW, Bugger H, Burkhoff D, Bruch L, Celermajer DS, Claggett B, Cleland JGF, Cutlip DE, Dauber I, Eicher JC, Gao Q, Gorter TM, Gustafsson F, Hayward C, van der Heyden J, Hasenfuss G, Hummel SL, Kaye DM, Komtebedde J, Massaro JM, Mazurek JA, McKenzie S, Mehta SR, Petrie MC, Post MC, Nair A, Rieth A, Silvestry FE, Solomon SD, Trochu JN, Van Veldhuisen DJ, Westenfeld R, Leon MB, Shah SJ; REDUCE LAP-HF-II Investigators. Latent Pulmonary Vascular Disease May Alter the Response to Therapeutic Atrial Shunt Device in Heart Failure. Circulation. 2022 May 24;145(21):1592-1604. doi: 10.1161/CIRCULATIONAHA.122.059486. Epub 2022 Mar 31. PubMed 35354306 ↗
  • Shah SJ, Borlaug BA, Chung ES, Cutlip DE, Debonnaire P, Fail PS, Gao Q, Hasenfuss G, Kahwash R, Kaye DM, Litwin SE, Lurz P, Massaro JM, Mohan RC, Ricciardi MJ, Solomon SD, Sverdlov AL, Swarup V, van Veldhuisen DJ, Winkler S, Leon MB; REDUCE LAP-HF II investigators. Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial. Lancet. 2022 Mar 19;399(10330):1130-1140. doi: 10.1016/S0140-6736(22)00016-2. Epub 2022 Feb 1. PubMed 35120593 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2022 (actual). Primary completion is estimated for Jul 2027, 56 months after the start.

Of 45 interventional studies with no phase under Heart Failure, Diastolic, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 62. This study's planned 56 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2022
First posted
Jun 21, 2022
StartActual
Nov 17, 2022
Primary completionEst.
Jul 2027
CompletionEst.
Mar 2031
Last update
Mar 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05425459
Lead sponsor
Corvia Medical
Responsible party
Sponsor
First posted
Jun 21, 2022
Start date
Nov 17, 2022
Primary completion
Jul 2027 (estimated)
Completion
Mar 2031 (estimated)
Last update
Mar 18, 2026

Study contacts

Sanjiv Shah, MD
principal investigator · Northwestern Memorial Hospital
Martin Leon, MD
principal investigator · Columbia University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion